Navigation Links
Amedica Signs Agreement with Kyocera for Commercial Manufacture of Silicon Nitride Medical Devices
Date:11/26/2013

SALT LAKE CITY, Nov. 26, 2013 /PRNewswire/ -- Amedica Corporation, a biomaterials company, today announced a collaboration with Kyocera Industrial Ceramics Corporation, a worldwide leading ceramics producer, to manufacture medical devices from Amedica's Silicon Nitride biomaterial at Kyocera's Vancouver, WA facility. This collaboration includes the manufacture of Amedica's FDA approved Silicon Nitride spinal interbody devices and will broaden Amedica's ability to meet market demand. 

As a biomaterial, Silicon Nitride has been shown to help promote bone growth and has anti-infective properties. Devices made from Silicon Nitride are semi-radiolucent with clearly visible boundaries enabling an exact view of intraoperative placement and postoperative fusion assessment via common imaging modalities. Amedica believes that these are essential characteristics that surgeons seek when choosing the ideal spinal interbody implant for their patients. Amedica has sold over 14,000 of these devices worldwide.

Eric Olson, President and CEO of Amedica Corporation, says, "There is an unmet need for advanced biomaterials in Orthopedics and Spine. We are seeing an increasing interest for our Silicon Nitride interbody devices and increased interest in this material for use in other applications and want to ensure a consistent supply for surgeons and more importantly, patients. As the world's number one producer of advanced ceramics* with vast experience in ensuring market demand is consistently fulfilled for innovative products, Kyocera is the ideal partner to help broaden availability of our novel biomaterial devices."

About Amedica Corporation

Amedica is a commercial biomaterial company focused on using its Silicon Nitride technology platform to develop, manufacture and sell a broad range of medical devices.  Amedica markets spinal fusion products and is developing product candidates for use in total hip and knee joint replacements.  Amedica is a privately owned company founded in 1996. The company operates an ISO 13485 certified manufacturing facility, and, its spine products are FDA cleared, CE marked, and are currently marketed in the US and select markets in Europe and South America. Amedica is based in Salt Lake City, Utah.

About KYOCERA

Kyocera Industrial Ceramics Corporation (www.kyocera.com/kicc), headquartered in Hendersonville, NC, specializes in applying advanced ceramic materials and components to solve the most demanding engineering challenges. It is a wholly-owned subsidiary of Kyocera International, Inc. of San Diego, the North American holding company for Kyocera Corporation.

Kyocera Corporation (NYSE: KYO) (TOKYO: 6971) (http://global.kyocera.com/), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as "advanced ceramics"). By combining these engineered materials with metals and plastics, and integrating them with other technologies, Kyocera has become a leading supplier of advanced ceramic components, medical products, solar power generating systems, telecommunications equipment, printers, copiers, electronic components, semiconductor packages and cutting tools. During the year ended March 31, 2013, the company's net sales totaled 1.28 trillion yen (approx. USD13.6 billion). The company is ranked #492 on Forbes magazine's 2013 "Global 2000" listing of the world's largest publicly traded companies.

http://www.ceramicindustry.com/articles/93444-ci-top-10-advanced-ceramic-manufacturers

Media Contacts  
Erika Kuzmicz 
Schwartz MSL  
(781) 684-0770  
AMEDICA@schwartzmsl.com

 


'/>"/>
SOURCE Amedica Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
2. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
3. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
4. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
5. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
6. Agendia Signs Contract with Blue Shield of California
7. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
8. Volition Signs Collaboration Agreement With Abcodia
9. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
10. Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions
11. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... The Children’s Tumor Foundation announced its ... tumors to grow on nerves throughout the body. It affects 1 in 3,000 people ... events held during the month of May, as well as online activities, Neurofibromatosis Awareness ...
(Date:5/3/2016)... , May 3, 2016 ... (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip (IVD ... (Academics Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, ... MarketsandMarkets, the market is expected to reach ... 7.63 Billion in 2015, growing at a ...
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the leader ... to its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories ... and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River ...
(Date:5/3/2016)... , May 3, 2016  Dr. Thomas ... surgeon in The Woodlands, Texas , ... 24 percent of treated fat cells in just 25-minutes, ... Close to 90 percent of Americans report feeling bothered ... Nonsurgical fat reduction procedures are a growing industry. This ...
Breaking Biology Technology:
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 /PRNewswire/ ... offer Oncimmune,s Early CDT®-Lung, a blood test to ... lung cancer Early CDT®-Lung test to its ... --> Early CDT®-Lung test to its clients which ... Oncimmune, a leader in early cancer detection, today announced ...
(Date:3/2/2016)... , March 2, 2016 ... addition of the "Global Biometrics as ... their offering. --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> Research and Markets ( ...
(Date:3/1/2016)... FRANCISCO , March 1, 2016  (RSAC Booth ... year, but a whopping $118 billion is lost to ... to overzealous and inaccurate fraud detection. At the RSA ... in the way companies handle authentication by devaluing the ... and behavioral analytics. --> ...
Breaking Biology News(10 mins):